Showcasing Next-Generation In Vitro Skin and Liver Models at BioAsia 2026
By Dr. Anshul Nigam
Scientist & Senior Business Development Manager, NEOJENBIO SAS
In an era defined by unprecedented global health challenges, the need for human-relevant, ethical, and predictive research technologies has never been more critical. Life sciences innovation today must not only be faster—but smarter, safer, and more responsible.
It is in this context that NEOJENBIO SAS is proud to participate in BioAsia 2026, Asia’s premier life sciences and healthcare event, taking place on 17–18 February 2026 at Hall 4, HITEX Exhibition Centre, Hyderabad.
As part of the official program, we will also take part in the 16th BioPark Visit (International Delegates only), fostering global collaboration and technology exchange.
Why BioAsia 2026 Matters
Now in its 23rd edition, BioAsia continues to serve as a powerful global platform, bringing together leaders from:
Life Sciences & Biotechnology
Pharmaceuticals
MedTech & HealthTech
Academia, Government & Regulatory Bodies
The conference accelerates partnerships, investments, and innovation that shape the future of healthcare worldwide.
Advancing Human-Relevant Research
At BioAsia 2026, NEOJENBIO SAS will showcase its advanced in vitro human-relevant skin and liver models, designed to support:
Chemical safety assessment
Drug discovery and development
Regulatory-aligned, ethical testing strategies
Our core focus addresses one of the most pressing needs in modern life sciences:
Reliable, reproducible, and human-predictive alternatives to traditional animal testing.
Advancing Chemical Safety and Drug Discovery
Visitors to our booth will learn how our platforms support better decision-making early in R&D pipelines through:
🔬 In Vitro Skin Models
Dermal toxicity
Skin irritation & corrosion
Permeability studies
🧬 In Vitro Liver Models
Hepatotoxicity assessment
Drug metabolism studies
Drug-Induced Liver Injury (DILI) evaluation
These human-relevant systems enhance predictive accuracy, reduce development timelines, and align with global regulatory expectations—empowering researchers across pharma, chemicals, cosmetics, and healthcare R&D.
Driving Ethical and Efficient Research
With increasing emphasis from regulators and industry on the **3Rs principle—Replacement, Reduction, and Refinement of animal use—**in vitro technologies are no longer optional; they are essential.
NEOJENBIO SAS designs its platforms to integrate seamlessly into existing R&D workflows, enabling organizations to meet scientific rigor, ethical responsibility, and regulatory compliance simultaneously.
Join Us at BioAsia 2026
We invite industry leaders, researchers, and collaborators to meet our Scientist and Senior Business Development Manager, Dr. Anshul Nigam, at BioAsia 2026 and explore how next-generation in vitro models can accelerate safer, faster, and more predictive innovation.
📍 BioAsia 2026 | Hyderabad
📅 17–18 February 2026
📧 contact@neojenbio.com
🌐 www.neojenbio.com